Clinical Outcomes Research, CPL Associates, Amherst, New York, USA.
Clin Infect Dis. 2010 Sep 15;51 Suppl 2:S198-208. doi: 10.1086/653520.
Since its introduction in the 1970s, outpatient parenteral antimicrobial therapy (OPAT) has become a standard modality for patients with many infections requiring long-term intravenous antibiotic therapy. Delivery of OPAT may occur in physicians' offices, hospital clinics, specialized infusion centers, and currently most often, patient's homes, often self-administered. Patients are selected for OPAT by physicians familiar with both the course of their infections, their personal suitability for outpatient care, and the availability of reimbursement. OPAT is reportedly safe, effective, practical, and cost-effective. An OPAT Outcomes Registry contains information from >11,000 antibiotic courses administered from 1997 through 2000. Although a number of studies are purported to analyze the economic impact of OPAT on health care, a comprehensive, clinical outcomes-based pharmacoeconomic analysis, as described here, has, to our knowledge, yet to be done.
自 20 世纪 70 年代问世以来，门诊患者的静脉用抗菌药物治疗（outpatient parenteral antimicrobial therapy，OPAT）已成为许多需要长期静脉用抗生素治疗的感染患者的标准治疗方法。OPAT 可以在医生办公室、医院门诊、专门的输液中心，目前最常见的是在患者家中进行，通常由患者自行给药。医生根据患者感染的病程、个人对门诊治疗的适宜性以及报销的可用性来选择 OPAT 患者。据报道，OPAT 安全、有效、实用且具有成本效益。OPAT 结果登记处包含了 1997 年至 2000 年期间 11000 多个抗生素疗程的信息。尽管有许多研究据称分析了 OPAT 对医疗保健的经济影响，但如这里所述的全面、基于临床结果的药物经济学分析，据我们所知，尚未进行。
